Validations Queue
63,896 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 17 of 53, 50 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
63,896
Reviewed
13
Filtered
2,618
page 17 / 53
Showing on page
50
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.60 | FDA ANDA091541: LOSARTAN POTASSIUM (LOSARTAN POTASSIUM) — MICRO LABS | fda 2026-04-10 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA220398: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — MANKIND PHARMA | fda 2026-04-16 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA219249: ITOVEBI (INAVOLISIB) — GENENTECH INC | fda 2026-04-15 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.60 | FDA ANDA217437: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — PH HEALTH | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA220529: BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE) — YICHANG HUMANWELL | fda 2026-05-04 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA207740: OMEPRAZOLE (OMEPRAZOLE) — DR REDDYS | fda 2026-04-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA219804: DOLUTEGRAVIR, LAMIVUDINE and TENOFOVIR DISOPROXIL FUMARATE (DOLUTEGRAVIR) — LACHMAN CONSULTANT SERVICES , INC. | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA215971: DEUTETRABENAZINE (DEUTETRABENAZINE) — AUROBINDO PHARMA LTD | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA NDA213756: KOSELUGO (SELUMETINIB SULFATE) — ASTRAZENECA | fda 2026-05-26 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA218197: TRUQAP (CAPIVASERTIB) — ASTRAZENECA | fda 2026-05-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA062943: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ALMAJECT | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA208047: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — DR REDDYS | fda 2026-06-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA BLA761063: EMGALITY (GALCANEZUMAB-GNLM) — ELI LILLY AND CO | fda 2026-06-05 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.60 | FDA ANDA220458: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — APOTEX | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA BLA761139: ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — DAIICHI SANKYO | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA021366: CRESTOR (ROSUVASTATIN CALCIUM) — ASTRAZENECA | fda 2026-04-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA220221: VERICIGUAT (VERICIGUAT) — TORRENT PHARMACEUTICALS LTD | fda 2026-04-20 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA206371: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — MICRO LABS | fda 2026-04-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA078947: LAMOTRIGINE (LAMOTRIGINE) — TORRENT PHARMS | fda 2026-04-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA NDA210793: NUPLAZID (PIMAVANSERIN TARTRATE) — ACADIA PHARMS INC | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA210480: LENALIDOMIDE (LENALIDOMIDE) — ALVOGEN | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA BLA761451: SAPHNELO (ANIFROLIMAB-FNIA) — ASTRAZENECA AB | fda 2026-04-24 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA216993: VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — DAIICHI SANKYO INC | fda 2026-04-29 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA BLA761349: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.60 | FDA NDA202667: COSOPT PF (DORZOLAMIDE HYDROCHLORIDE) — THEA PHARMA | fda 2026-04-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA204819: ADEMPAS (RIOCIGUAT) — BAYER HLTHCARE | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA210040: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — AMNEAL PHARMS | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA212438: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ENCUBE | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA218197: TRUQAP (CAPIVASERTIB) — ASTRAZENECA | fda 2026-05-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.60 | FDA NDA202293: FARXIGA (DAPAGLIFLOZIN) — ASTRAZENECA AB | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA076781: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — HIKMA FARMACEUTICA | fda 2026-04-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA214957: GABAPENTIN (GABAPENTIN) — ASCENT PHARMS INC | fda 2026-04-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA215833: PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — NOVARTIS | fda 2026-04-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA021342: LEVO-T (LEVOTHYROXINE SODIUM) — CEDIPROF INC | fda 2026-05-04 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA216081: GADOBUTROL (GADOBUTROL) — HENGRUI PHARMA | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA219835: VEPPANU (VEPDEGESTRANT) — ARVINAS OPERATIONS | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA219494: SPIRONOLACTONE (SPIRONOLACTONE) — GRAVITI PHARMS | fda 2026-05-12 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA ANDA209224: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.60 | FDA BLA761111: NYVEPRIA (PEGFILGRASTIM-APGF) — HOSPIRA INC | fda 2026-05-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA204114: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — NOVARTIS | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA208028: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — INVAGEN PHARMS | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA219552: PEMIGATINIB (PEMIGATINIB) — SANDOZ INC | fda 2026-06-01 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA211535: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — CIPLA | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA211533: DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MSN | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA NDA207318: NUPLAZID (PIMAVANSERIN TARTRATE) — ACADIA PHARMS INC | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA207694: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — LUPIN | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA216537: CARBIDOPA AND LEVODOPA (CARBIDOPA) — AUROBINDO PHARMA LTD | fda 2026-05-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA209224: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.60 | FDA ANDA208058: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — HERITAGE PHARMA AVET | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA219346: ANDA219346 ((unspecified)) — SANDOZ INC | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% |